Table 3. Characteristics of CB transplant recipients.

CSA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; Bu, busulfan; Cy, Cytoxan; Flu, fludarabine; TBI, total body irradiation.

P2891P3010P3275
SexMMM
Age (years)521
DiseaseFanconi anemiaALLSCID
Donor HLAA*23:01,30:01;
B*58:01,57:01;
C*07:18,07:01;
DRB1*15:03,15:02;
DQB1*08:02,06:01
A*02:AGA,33:01;
B*07:ANVB,14:02;
C*05:01,08:02;
DRB1*03:01,15:01;
DQB1*02:01,06:02
A*01:BMMP,02:01;
B*08:01:01,39:05;
C*07:WTR,07:WCP;
DRB1:
03:01,04:07:01;
DQB1:
02:01:01,03:02:01
HLA match5 of 65 of 66 of 6
Conditioning
regimen
Flu/Cy/TBIFlu/Cy/TBIBu/Cy/Flu
GVHD
prophylaxis
CSA and MMFCSAPred and MMF
Immune
suppression
at time of
T cell infusion
CSACSAPred and MMF
Recipient
CMV
serostatus
PositivePositiveNot determined but
PCR-negative
Viral
infections
CMV, adenovirusNoneNone
Cell dose
(cells/m2)
5 × 1065 × 1061 × 107
Concurrent
antiviral
drugs
Foscarnet →
ganciclovir
NoneNone
Viral outcomeCMV reactivation
and adenovirus
infection resolved
No viral
reactivations
No viral
reactivations
Cell dose
(cells/m2)
5 × 1065 × 1061 × 107
Duration of
cell culture
(days)
575055